Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
For primary surgical treatment of prostate cancer the investigators compare the classic open surgery (radical retropubic prostatectomy, RRP) versus robot-assisted laparoscopic surgery (RALP). Oncological results are obtained at standard follow-up consultations through Prostate-Specific Antigen (PSA) measurement to detect biochemical recurrence. Functional results (continence, potency, quality of life) are obtained through standardised questionnaires. Currently the investigators perform all of their prostatectomies in a robot-assisted manner. For results of the open surgery the investigators send questionnaires to patients who had the operation in the past.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Radical Retropubic prostatectomy (RRP) | Men who underwent open radical prostatectomy in the past at our centre. | ||
| Robot-assisted laparoscopic prostatectomy (RALP) | Men who undergo robot-assisted laparoscopic prostatectomy at our centre. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Biochemical recurrence at follow-up. | PSA measurement in the serum should not be > or = 0,20 ng/ml. | 3 months after prostatectomy |
| Biochemical recurrence at follow-up | PSA measurement in the serum should not be > or = 0,20 ng/ml. | 6 months after prostatectomy |
| Biochemical recurrence at follow-up. | PSA measurement in the serum should not be > or = 0,20 ng/ml. | 9 months after prostatectomy |
| Biochemical recurrence at follow-up. | PSA measurement in the serum should not be > or = 0,20 ng/ml. | 1 year after prostatectomy |
| Biochemical recurrence at follow-up. | PSA measurement in the serum should not be > or = 0,20 ng/ml. | 6-monthly follow up between 1 and 5 years after prostatectomy. |
| Measure | Description | Time Frame |
|---|---|---|
| Functional assessment concerning continence. | Patients need to fill out questionnaires (EORTC QLQ-C30, QLQ-PR25, ICIQ mLUTS and UI SF and IIEF). The patients in the radical retropubic prostatectomy group only fill out the questionnaires once. | after 1, 3, 12 and 24 months |
| Functional assessment concerning potency. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Men who were surgically treated or who are being surgically treated for prostate cancer.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicolaas Lumen, MD | University Hospital, Ghent | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ghent University Hospital | Ghent | 9000 | Belgium |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Patients need to fill out questionnaires (EORTC QLQ-C30, QLQ-PR25, ICIQ mLUTS and UI SF and IIEF). The patients in the radical retropubic prostatectomy group only fill out the questionnaires once. |
| after 1, 3, 12 and 24 months |
| Functional assessment concerning quality of life. | Patients need to fill out questionnaires (EORTC QLQ-C30, QLQ-PR25, ICIQ mLUTS and UI SF and IIEF). The patients in the radical retropubic prostatectomy group only fill out the questionnaires once. | after 1, 3, 12 and 24 months |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |